View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2018	Jul. 31, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Trading Symbol	LMAT
Entity Registrant Name	LEMAITRE VASCULAR INC
Entity Central Index Key	0001158895
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		19,461,986

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 19,638	$ 19,096
Short-term marketable securities	33,298	22,564
Accounts receivable, net of allowances of $494 at June 30, 2018, and $349 at December 31, 2017	15,230	15,000
Inventory and other deferred costs	21,669	21,046
Prepaid expenses and other current assets	2,529	2,605
Total current assets	92,364	80,311
Property and equipment, net	12,235	12,378
Goodwill	23,602	23,844
Other intangibles, net	7,358	8,234
Deferred tax assets	1,347	1,378
Other assets	194	178
Total assets	137,100	126,323
Current liabilities:
Accounts payable	1,657	1,543
Accrued expenses	11,286	9,770
Acquisition-related obligations	172	1,876
Total current liabilities	13,115	13,189
Deferred tax liabilities	2,175	2,176
Other long-term liabilities	1,066	1,188
Total liabilities	16,356	16,553
Stockholders' equity:
Preferred stock, $0.01 par value; authorized 3,000,000 shares; none outstanding
Common stock, $0.01 par value; authorized 37,000,000 shares; issued 20,836,847 shares at June 30, 2018, and 20,745,041 shares at December 31, 2017	208	207
Additional paid-in capital	95,122	93,127
Retained earnings	38,234	28,333
Accumulated other comprehensive loss	(3,207)	(2,289)
Treasury stock, at cost; 1,480,250 shares at June 30, 2018 and 1,480,101 shares at December 31, 2017	(9,613)	(9,608)
Total stockholders' equity	120,744	109,770
Total liabilities and stockholders' equity	$ 137,100	$ 126,323

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 494	$ 349
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	37,000,000	37,000,000
Common stock, shares issued	20,836,847	20,745,041
Treasury stock, at cost	1,480,250	1,480,101

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Statement [Abstract]
Net sales	$ 27,020	$ 25,753	$ 53,014	$ 49,892
Cost of sales	8,028	8,238	15,548	15,023
Gross profit	18,992	17,515	37,466	34,869
Sales and marketing	6,792	6,599	13,882	13,553
General and administrative	4,547	3,747	9,244	8,295
Research and development	1,988	1,634	3,813	3,292
Gain on divestiture	(5,876)		(5,876)
Total operating expenses	7,451	11,980	21,063	25,140
Income from operations	11,541	5,535	16,403	9,729
Other income (expense):
Interest income	165	32	260	52
Foreign currency gain (loss)	(159)	(102)	(200)	(76)
Income before income taxes	11,547	5,465	16,463	9,705
Provision for income taxes	2,796	833	3,859	1,854
Net income	$ 8,751	$ 4,632	$ 12,604	$ 7,851
Earnings per share of common stock:
Basic	$ 0.45	$ 0.25	$ 0.65	$ 0.42
Diluted	$ 0.43	$ 0.23	$ 0.62	$ 0.40
Weighted-average shares outstanding:
Basic	19,320	18,816	19,301	18,724
Diluted	20,260	19,975	20,243	19,855
Cash dividends declared per common share	$ 0.070	$ 0.055	$ 0.140	$ 0.110

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Net income	$ 8,751	$ 4,632	$ 12,604	$ 7,851
Other comprehensive income (loss):
Foreign currency translation adjustment, net	(1,223)	1,019	(895)	1,639
Unrealized gain (loss) on short-term marketable securities	22		(23)
Total other comprehensive income	(1,201)	1,019	(918)	1,639
Comprehensive income	$ 7,550	$ 5,651	$ 11,686	$ 9,490

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Operating activities
Net income	$ 12,604	$ 7,851
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,102	1,962
Stock-based compensation	1,257	959
Fair value adjustment to contingent consideration obligations	42
Provision for doubtful accounts	146	104
Provision for inventory write-downs	170	184
Gain on divestitures	(5,876)
Foreign currency transaction loss	96	(20)
Changes in operating assets and liabilities:
Accounts receivable	(552)	(1,067)
Inventory and other deferred costs	(1,306)	(767)
Prepaid expenses and other assets	26	(756)
Accounts payable and other liabilities	(82)	(550)
Net cash provided by operating activities	8,627	7,900
Investing activities
Purchases of property and equipment and other assets	(1,230)	(2,444)
Purchases of short-term marketable securities	(10,757)
Proceeds from divestiture	7,400
Net cash used in investing activities	(4,587)	(2,444)
Financing activities
Payments of deferred acquisition consideration	(1,142)	(388)
Proceeds from issuance of common stock	738	2,301
Purchase of treasury stock	(5)
Common stock cash dividend paid	(2,704)	(2,065)
Net cash provided by financing activities	(3,113)	(152)
Effect of exchange rate changes on cash and cash equivalents	(385)	528
Net increase in cash and cash equivalents	542	5,832
Cash and cash equivalents at beginning of period	19,096	24,288
Cash and cash equivalents at end of period	$ 19,638	$ 30,120

Organization and Basis for Presentation

6 Months Ended

Jun. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Basis for Presentation

1. Organization and Basis for Presentation

Description of Business

Unless the context requires otherwise, references to LeMaitre Vascular, we, our, and us refer to LeMaitre Vascular, Inc. and our subsidiaries. We develop, manufacture, and market medical devices and implants used primarily in the field of vascular surgery. We also derive revenues from the processing and cryopreservation of human tissues for implantation into patients. We operate in a single segment in which our principal product lines include the following: anastomotic clips, angioscopes, balloon catheters, biologic vascular grafts, biologic vascular patches, carotid shunts, powered phlebectomy devices, radiopaque marking tape, remote endarterectomy devices, synthetic vascular grafts, and valvulotomes. Our offices are located in Burlington, Massachusetts; Fox River Grove, Illinois; Vaughan, Canada; Sulzbach, Germany; Milan, Italy; Madrid, Spain; North Melbourne, Australia; Tokyo, Japan; and Shanghai, China.

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal, recurring adjustments considered necessary for a fair presentation of the results of these interim periods have been included. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Actual results may differ from these estimates. Our estimates and assumptions, including those related to bad debts, inventories, intangible assets, sales returns and discounts, share-based compensation, and income taxes are updated as appropriate. The results for the six months ended June 30, 2018 are not necessarily indicative of results to be expected for the entire year. The information contained in these interim financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2017, including the notes thereto, included in our Form 10-K filed with the Securities and Exchange Commission (SEC) on March 9, 2018.

Consolidation

Our consolidated financial statements include the accounts of LeMaitre Vascular and the accounts of our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Revenue Recognition

Our revenue is derived primarily from the sale of disposable or implantable devices used during vascular surgery. We sell primarily directly to hospitals, and to a lesser extent to distributors. We also occasionally enter into consigned inventory arrangements with either hospitals or distributors on a limited basis. Following our acquisition of the RestoreFlow allograft business, we also derive revenues from human tissue cryopreservation services. These service revenues are recognized when services have been provided and the tissue has been shipped to the customer, provided all other revenue recognition criteria discussed below have been met.

On January 1, 2018 we adopted the provisions of ASU 2014-09, Revenue from Contracts with Customers (Topic 606). We used the modified retrospective method of adoption under which the comparative information was not restated and will continue to be reported under the standard in effect for those periods. The adoption of this standard was not material to our financial statements and there was no cumulative effect adjustment to the opening balance of retained earnings required. The core principle of Topic 606 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard explains that to achieve the core principle, an entity should take the following actions:

Step 1: Identify the contract with a customer

Step 2: Identify the performance obligations in the contract

Step 3: Determine the transaction price

Step 4: Allocate the transaction price

Step 5: Recognize revenue when or as the entity satisfies a performance obligation

Revenue is recognized when or as a company satisfies a performance obligation by transferring a promised good or service to a customer (which is when the customer obtains control of that good or service).

We generally reference customer purchase orders to determine the existence of a contract. Orders that are not accompanied by a purchase order are confirmed with the customer either in writing or verbally. The purchase orders or similar correspondence, once accepted, identify the performance obligations as well as the transaction price, and otherwise outline the rights and obligations of each party. We allocate the transaction price of each contract among the performance obligations in accordance with the pricing of each item specified on the purchase order, which is in turn based on standalone selling prices per our published price lists. In cases where we discount products or provide certain items free of charge, we allocate the discount proportionately to all performance obligations, unless it can be demonstrated that the discount should be allocated entirely to one or more, but not all, of the performance obligations.

We recognize revenue, net of allowances for returns and discounts, fees paid to group purchasing organizations, and any sales and value added taxes required to be invoiced, which we have elected to exclude from the measurement of the transaction price as allowed by the standard, at the time of shipment (taking into consideration contractual shipping terms), or in the case of consigned inventory, when it is consumed. Shipment is the point at which control of the product and title passes to our customers, and at which LeMaitre has a present right to receive payment for the goods. Our shipping and handling activities generally occur prior to the customer taking control of the goods, but in instances where part of these services occurs after the customer gains control, we have made a policy election as allowed under the standard to account for them as activities to fulfill the promise to transfer the goods as opposed to a performance obligation.

Below is a disaggregation of our revenue by major geographic area, which is among the primary categorizations used by management in evaluating financial performance, for the periods indicated (in thousands):


	Six months ended June 30,
	2018		2017
Americas	$	31,942	$	31,069
Europe, Middle East and Africa		17,829		15,734
Asia/Pacific Rim		3,243		3,089

Total	$	53,014	$	49,892

Except as discussed in Note 6, we do not carry any contract assets or contract liabilities, as there are generally no unbilled amounts due from customers under contracts for which we have partially satisfied performance obligations, or amounts received from customers for which we have not satisfied performance obligations. We satisfy our performance obligations under revenue contracts within a very short time period from receipt of the orders, and payments from customers are typically received within 30 to 60 days of fulfillment of the orders, except in certain geographies such as Spain and Italy where the payment cycle is customarily longer. Accordingly, there is no significant financing component to our revenue contracts. Additionally, we have elected as a policy that incremental costs (such as commissions) incurred to obtain contracts are expensed as incurred, due to the short-term nature of the contracts.

Customers returning products may be entitled to full or partial credit based on the condition and timing of the return. To be accepted, a returned product must be unopened (if sterile), unadulterated, and undamaged, must have at least 18 months remaining prior to its expiration date, or twelve months for our hospital customers in Europe, and generally be returned within 30 days of shipment. These return policies apply to sales to both hospitals and distributors. The amount of products returned to us, either for exchange or credit, has not been material. Nevertheless, we provide for an allowance for future sales returns based on historical return experience, which requires judgment. Our cost of replacing defective products has not been material and is accounted for at the time of replacement.

Recent Accounting Pronouncements

In February 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2018-02, Income Statement – Reporting Other Comprehensive Income (Topic 220), which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. Consequently, the amendments eliminate the stranded tax effects resulting from the Tax Cuts and Jobs Act and is expected to improve the usefulness of information reported to financial statement users. However, because the amendments only relate to the reclassification of the income tax effects of the Tax Cuts and Jobs Act, the underlying guidance that requires that the effect of a change in tax laws or rates be included in income from continuing operations is not affected. The amendments in this ASU also require certain disclosures about stranded tax effects. The new standard is effective for us beginning January 1, 2019, with early adoption permitted. The adoption of this standard is not expected to have a material impact on our financial statements.

In January 2017, the FASB issued ASU 2017-04, which, among other provisions, eliminates “step 2” from the goodwill impairment test. The annual, or interim, goodwill impairment test will be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The new standard is effective for us beginning January 1, 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on our financial statements.

In February 2016, the FASB issued its new lease accounting guidance in ASU No. 2016-02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. The new lease guidance simplifies the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. Lessees will no longer be provided with a source of off-balance sheet financing. The standard is effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years (i.e., January 1, 2019, for a calendar year entity). Early application is permitted. Entities have the option of using either a modified retrospective approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, or else a transition option allowing lessees to not apply the new lease standard in comparative periods but instead recognize a cumulative-effect adjustment to retained earnings as of the date of adoption. The modified retrospective approach would not require any transition accounting for leases that expired before the earliest comparative period presented. Lessees and lessors may not apply a full retrospective transition approach. Our assessment of the impact of adopting this standard is underway, including identifying all of our leases, performing a preliminary analysis of the amounts of lease liabilities and right-of-use assets to be recorded and reviewing potential changes to our disclosures on leases. Based on this preliminary assessment we do not expect the adoption of this standard to have a significant impact on our consolidated statement of operations. However, we expect that the recognition of right-of-use assets and corresponding lease liabilities could have a significant impact on our consolidated balance sheet.

Income Tax Expense

6 Months Ended

Jun. 30, 2018

Income Tax Disclosure [Abstract]

Income Tax Expense

2. Income Tax Expense

As part of the process of preparing our consolidated financial statements we are required to determine our income taxes in each of the jurisdictions in which we operate. This process involves estimating our actual current tax expense together with assessing temporary differences resulting from recognition of items for income tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within our consolidated balance sheet. We must then assess the likelihood that our deferred tax assets will be recovered from taxable income during the carryback period or in the future; and to the extent we believe that recovery is not more likely than not, we must establish a valuation allowance. To the extent we establish a valuation allowance or increase this allowance in a period, we must reflect this increase as an expense within the tax provision in the statement of operations. We do not provide for income taxes on undistributed earnings of foreign subsidiaries, as our intention is to permanently reinvest these earnings.

The Tax Cut and Jobs Act of 2017 (the Tax Act) changed many aspects of U.S. corporate income taxation and included a reduction of the corporate income tax rate from 35% to 21%, implementation of a territorial tax system, and imposition of a tax on deemed repatriated earnings of foreign subsidiaries (the Transition Tax). We estimated the impact of the Tax Act in our financial statements as of December 31, 2017. We recorded $0.6 million in tax expense related to the Transition Tax and recognized $1.0 million in tax benefit related to the remeasurement of deferred taxes to the 21% tax rate. We may subsequently identify adjustments to our estimated Transition Tax and/or deferred tax remeasurement while preparing our 2017 U.S. tax return, finalizing foreign earnings and profits calculations, or taking into account additional guidance issued by the IRS. Any such revisions will be treated in accordance with the measurement period guidance outlined in Staff Accounting Bulletin No. 118.

We recognize, measure, present and disclose in our financial statements any uncertain tax positions that we have taken, or expect to take on a tax return. We operate in multiple taxing jurisdictions, both within and without the United States, and may be subject to audits from various tax authorities. Management’s judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities, liabilities for uncertain tax positions, and any valuation allowance recorded against our net deferred tax assets. We will monitor the realizability of our deferred tax assets and adjust the valuation allowance accordingly.

Our policy is to classify interest and penalties related to unrecognized tax benefits as income tax expense.

Our 2018 income tax expense varies from the statutory rate mainly due to the generation of federal and state tax credits, permanent items, and different statutory rates from our foreign subsidiaries. Additionally, in the second quarter of 2018, we recognized certain discrete items primarily related to the exercise of stock options. Our 2017 income tax expense varied from the statutory rate mainly due to federal and state tax credits, permanent items, different statutory rates from our foreign entities, and discrete stock option exercises.

We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of June 30, 2018, the gross amount of unrecognized tax benefits exclusive of interest and penalties was $578,000. We remain subject to examination until the statute of limitations expires for each respective tax jurisdiction. The statute of limitations will be open with respect to these tax positions until 2025. A reconciliation of beginning and ending amount of our unrecognized tax benefits is as follows:


	Six months ended June 30, 2018
	(in thousands)
Unrecognized tax benefits as of December 31, 2017		525
Additions for tax positions of current year		48
Additions for tax positions of prior years		5
Reductions for settlements with taxing authorities		—
Reductions for lapses of the applicable statutes of limitations		—

Unrecognized tax benefits as of June 30, 2018		578

As of June 30, 2018, a summary of the tax years that remain subject to examination in our taxing jurisdictions is as follows:


United States			2014 and forward
Foreign			2011 and forward

Inventories and Other Deferred Costs

6 Months Ended

Jun. 30, 2018

Text Block [Abstract]

Inventories and Other Deferred Costs

3. Inventories and Other Deferred Costs

Inventories and other deferred costs consist of the following:


	June 30, 2018		December 31, 2017
	(in thousands)
Raw materials	$	3,549	$	3,200
Work-in-process		4,253		3,745
Finished products		12,668		12,278
Other deferred costs		1,199		1,823

Total inventory and other deferred costs	$	21,669	$	21,046

We had inventory on consignment of $1.4 million at both June 30, 2018 and December 31, 2017.

Other deferred costs relate to our RestoreFlow allograft offering and include costs incurred for the preservation of human vascular tissues available for shipment, tissues currently in active processing, and tissues held in quarantine pending release to implantable status. By federal law, human tissues cannot be bought or sold. Therefore, the vascular tissues we preserve are not held as inventory, and the costs we incur to procure and process them are instead accumulated and deferred. These costs include fixed and variable overhead costs associated with the cryopreservation process, including primarily direct labor costs, tissue recovery fees, inbound freight charges, indirect materials and facilities costs. General and administrative expenses and selling expenses associated with the provision of these services are expensed as incurred.

Acquisitions and Divestitures

6 Months Ended

Jun. 30, 2018

Reddick Cholangiogram Catheter and Reddick Saye-Screw [Member]

Acquisitions and Divestitures

4. Acquisitions and Divestitures

Acquisitions are accounted for using the acquisition method, and the acquired companies’ results have been included in the accompanying consolidated financial statements from their respective dates of acquisition. In each case for the acquisitions disclosed below, pro forma information assuming the acquisition had occurred at the beginning of the earliest period presented is not included, as the impact is immaterial.

Our acquisitions have historically been made at prices above the fair value of the acquired identifiable assets, resulting in goodwill, due to expectations of synergies that will be realized by combining businesses. These synergies include the use of our existing sales channel to expand sales of the acquired businesses’ products and services, consolidation of manufacturing facilities, and the leveraging of our existing administrative infrastructure.

The fair market valuations associated with these transactions fall within Level 3 of the fair value hierarchy, due to the use of significant unobservable inputs to determine fair value. The fair value measurements were calculated using unobservable inputs, primarily using the income approach, specifically the discounted cash flow method. The amount and timing of future cash flows within our analysis was based on our due diligence models, most recent operational budgets, long range strategic plans and other estimates. Our assumptions associated with these Level 3 valuations are discussed below and in Note 13 to these financial statements.

RestoreFlow Allografts

On November 10, 2016, we entered into an agreement to acquire the assets of Restore Flow Allografts, LLC, a provider of human vascular tissue processing and cryopreservation services, for an initial purchase price of $12 million, with three additional payments of up to $2 million each ($6 million in total), depending upon the satisfaction of certain contingencies. One payment of $2 million was due not later than 15 days following the expiration of the 18 month period following the closing date, subject to reductions as specified in the agreement for each calendar month that certain retained employees were not employed by us due to resignation without good reason, or termination for cause, both as defined in the agreement. The portion of this payment that was to be paid to retained employees and that was contingent on their continued employment, estimated at $0.9 million, was being accounted for as post-combination compensation expense rather than purchase consideration. The remaining $1.1 million that was payable to non-employee investors but that was also contingent on the continued employment of the retained employees had been accounted for as contingent purchase consideration, at an acquisition-date fair value of $0.9 million. During the three months ended June 30, 2018 we paid this $2 million liability as the contingency was met.

There are also two potential earn-out payments under the agreement. The first earn-out was to be calculated at 50% of the amount by which net revenue in the first 12 months following the closing exceeded $6 million, with such payout not to exceed $2 million. This milestone was not met and accordingly no amount was paid out. The second earn-out is calculated at 50% of the amount by which net revenue in the second 12 months following the closing exceeds $9 million, with such payout not to exceed $2 million. These earn-outs were accounted for as contingent consideration, at an acquisition-date fair value of $0.1 million for the two earn-outs combined. This valuation was derived by utilizing an option pricing model technique incorporating, among other inputs, management’s forecasts of future revenues, the expected volatility of revenues, and an estimated weighted average cost of capital of 14.1% to account for the risk of achievement of the revenue forecasts as well as the time value of money between acquisition date and the payment date.

The RestoreFlow business derives revenue from human tissue preservation services, in particular the processing and cryopreservation of veins and arteries. By federal law, human tissues cannot be bought or sold. Therefore, the tissues we obtain and preserve are not held as inventory, and the costs we incur to procure and process vascular tissues are instead accumulated and deferred. Revenues are recognized for the provision of cryopreservation services rather than product sales.

The acquired assets included intellectual property, permits and approvals, data and records, equipment and furnishings, accounts receivable, inventory, literature, and customer and supplier information. We also assumed certain accounts payable. We accounted for the acquisition as a business combination.

The following table summarizes the final purchase price allocation:


	Allocated Fair Value
	(in thousands)
Accounts receivable	$	394
Deferred cryopreservation costs		2,583
Equipment and supplies		125
Accounts payable		(286	)
Intangible assets		4,544
Goodwill		5,599

Purchase price	$	12,959

The goodwill is deductible for tax purposes over 15 years.

The following table reflects the allocation of purchase consideration to the acquired intangible assets and related estimated useful lives:


	Allocated Fair Value		Weighted Average Useful Life
	(in thousands)
Non-compete agreements	$	180		5.0 years
Tradename		271		9.0 years
Procurement contracts		617		9.0 years
Technology		2,793		10.5 years
Customer relationships		683		12.5 years

Total intangible assets	$	4,544

The weighted-average amortization period of the acquired intangible assets was 10.3 years.

ProCol Biologic Graft

On March 18, 2016, we acquired the ProCol biologic vascular graft (“ProCol”) business for $2.7 million from Hancock Jaffe Laboratories, Inc. (HJL) and CryoLife, Inc. (CRY). HJL was the owner and manufacturer of ProCol and CRY was the exclusive distributor of the ProCol graft. CRY also owned an option to purchase the ProCol business, which we acquired from CRY. We bought finished goods inventory and other ProCol related assets from CRY for $2.0 million, which was paid in full at closing. We bought other ProCol assets from HJL for $0.7 million, 50% of which was paid at closing, with the remainder paid at subsequent dates as specified in the agreement. Additional consideration is payable to HJL for a three-year period following the closing, calculated at 10% of ProCol revenues. This additional consideration was initially valued at $0.3 million and is being re-measured each reporting period until the payment requirement ends, with any adjustments reported in income from operations. To date since the acquisition there have been no material adjustments.

Assets acquired included inventory, intellectual property and a related license, the ProCol trade name, customer lists, non-compete agreements and certain equipment and supplies. We did not assume any liabilities. We accounted for the acquisition as a business combination. The purchase accounting is complete.

The following table summarizes the purchase price allocation as of the acquisition date:


	Allocated Fair Value
	(in thousands)
Inventory	$	2,080
Manufacturing equipment and supplies		25
Intangible assets		620
Goodwill		318

Purchase price	$	3,043

The goodwill is deductible for tax purposes over 15 years.

The following table reflects the allocation of purchase consideration to the acquired intangible assets and related estimated useful lives:


	Allocated Fair Value		Weighted Average Useful Life
	(in thousands)
Non-compete agreement	$	84		5.0 years
Tradename		109		9.5 years
Intellectual property		277		9.0 years
Customer relationships		150		9.0 years

Total intangible assets	$	620

The weighted-average amortization period of the acquired intangible assets was 8.6 years.

Reddick Divestiture

On April 5, 2018, we entered into an asset purchase agreement with Specialty Surgical Instrumentation, Inc. to sell the inventory, intellectual property and other assets associated exclusively with our Reddick cholangiogram catheter and Reddick Saye-Screw product lines for $7.4 million. In connection with this divestiture we at the same time entered into a transition services agreement under which we will continue to manufacture and supply these products to the buyer for a period of up to two years unless extended by both parties, as well as a balloon supply agreement under which we will supply latex balloons, a component of the cholangiogram catheters, to the buyer for a period of up to six years unless extended by both parties. During the three months ending June 30, 2018 we recorded a gain in connection with these agreements of $5.9 million. The following table summarizes the allocation of consideration received:


	Allocated Fair Value
	(in thousands)
Inventory	$	308
Deferred revenue—transition services agreement		1,081
Goodwill		135
Gain on divestiture		5,876

Consideration received	$	7,400

Under the terms of the transition services agreement, we have agreed to manufacture the Reddick products for the buyer at prices at or in some cases below our cost. We allocated a portion of the consideration received to this agreement to reflect it at fair value and recorded it as deferred revenue. As the products are sold to the buyer, we amortize a portion of the deferred revenue to adjust the gross margin on the sale to fair value on a specific identification basis. Additionally, as the Reddick product lines that were divested constituted a business, we allocated a portion of our goodwill to this divestiture based on the fair value of the business sold in relation to the fair value of the business that will be retained.

Goodwill and Other Intangibles

6 Months Ended

Jun. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangibles

5. Goodwill and Other Intangibles

Goodwill consists of the following as of June 30, 2018:


	(in thousands)
Balance at December 31, 2017	$	23,844
Divestiture adjustment		(135	)
Effects of currency exchange		(107	)

Balance at June 30, 2018	$	23,602

Other intangible assets consist of the following:


	June 30, 2018						December 31, 2017
	Gross Carrying Value		Accumulated Amortization		Net Carrying Value		Gross Carrying Value		Accumulated Amortization		Net Carrying Value
	(in thousands)
Product technology	$	10,197	$	5,295	$	4,902	$	10,267	$	4,908	$	5,359
Trademarks and licenses		1,943		1,511		432		1,948		1,468		480
Customer relationships		5,317		3,535		1,782		5,383		3,299		2,084
Other intangible assets		1,567		1,325		242		1,575		1,264		311

Total identifiable intangible assets	$	19,024	$	11,666	$	7,358	$	19,173	$	10,939	$	8,234

These intangible assets are being amortized over their useful lives ranging from 3 to 13 years. The weighted-average amortization period for these intangibles as of June 30, 2018 is 8.0 years. Amortization expense is included in general and administrative expense and was as follows for the periods indicated.


	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017
	(in thousands)				(in thousands)
Amortization expense	$	414	$	456	$	832	$	910

We estimate that amortization expense for the remainder of 2018 and for each of the five succeeding fiscal years will be as follows:


	Year ended December 31,
	2018		2019		2020		2021		2022		2023
	(in thousands)
Amortization expense	$	750	$	1,377	$	1,122	$	923	$	713	$	680

Accrued Expenses and Other Long-term Liabilities

6 Months Ended

Jun. 30, 2018

Payables and Accruals [Abstract]

Accrued Expenses and Other Long-term Liabilities

6. Accrued Expenses and Other Long-term Liabilities

Accrued expenses consist of the following:


	June 30, 2018		December 31, 2017
	(in thousands)
Compensation and related taxes	$	5,618	$	6,494
Income and other taxes		1,565		703
Professional fees		61		35
Deferred revenue		951		—
Other		3,091		2,538

Total	$	11,286	$	9,770

As discussed in Note 4 above, deferred revenue relates to our divestiture of the Reddick product line and an associated transition services agreement that we entered into contemporaneously with the divestiture under which we agreed to manufacture and sell product to the buyer at prices at or below our cost. We allocated a portion of the consideration received from the divestiture to this transition services agreement to reflect it at fair value and recorded it as deferred revenue. As the products are sold to the buyer, which we expect will occur over approximately the next twelve, months, we amortize a portion of the deferred revenue to adjust the gross margin on the sale to fair value on a specific identification basis. Additionally, as the Reddick product lines that were divested constituted a business, we allocated a portion of our goodwill to this divestiture based on the fair value of the business sold in relation to the fair value of the business that will be retained. The following table summarizes the changes in the deferred revenue balance during the three months ended June 30, 2018:


	June 30, 2018
	(in thousands)
Beginning contract liability balance	$	—
Deferred revenue recorded		1,081
Revenue recognized upon satisfaction of performance obligations in the period		(130	)

Ending balance	$	951

Other long-term liabilities consist of the following:


	June 30, 2018		December 31, 2017
	(in thousands)
Aquisition-related liabilities	$	—	$	127
Deferred rent		547		561
Income taxes		327		321
Other		192		179

Total	$	1,066	$	1,188

Segment and Enterprise-Wide Disclosures

6 Months Ended

Jun. 30, 2018

Segment Reporting [Abstract]

Segment and Enterprise-Wide Disclosures

7. Segment and Enterprise-Wide Disclosures

Under Accounting Standards Codification Topic 280, Segment Reporting, operating segments are defined as components of an enterprise for which separate, discrete financial information is available and evaluated by the chief operating decision-maker in making decisions on how to allocate resources and assess performance. We view our operations and manage our business as one operating segment. No discrete operating information is prepared by us except for sales by product line and by legal entity for local reporting purposes.

Most of our revenues are generated in the United States, Germany, and other European countries as well as in Canada, Japan and China. Substantially all of our assets are located in the United States. Net sales to unaffiliated customers by country were as follows:


	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017
	(in thousands)				(in thousands)
United States	$	14,864	$	14,932	$	29,684	$	28,979
Germany		3,257		2,854		6,364		5,739
Other countries		8,899		7,967		16,966		15,174

Net Sales	$	27,020	$	25,753	$	53,014	$	49,892

Share-based Compensation

6 Months Ended

Jun. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-based Compensation

9. Share-based Compensation

Our Third Amended and Restated 2006 Stock Option and Incentive Plan allows for granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, unrestricted stock awards and deferred stock awards to our officers, employees, directors and consultants.

The components of share-based compensation expense were as follows:


	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017
	(in thousands)				(in thousands)
Stock option awards	$	391	$	310	$	780	$	624
Restricted stock units		245		161		477		335

Total share-based compensation	$	636	$	471	$	1,257	$	959

Stock-based compensation is included in our statements of operations as follows:


	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017
	(in thousands)				(in thousands)
Cost of sales	$	83	$	41	$	148	$	94
Sales and marketing		136		114		273		230
General and administrative		351		271		702		546
Research and development		66		45		134		89

Total stock-based compensation	$	636	$	471	$	1,257	$	959

We did not grant any options during the six months ended June 30, 2018. Option grants during the six months ended June 30, 2017 were not material. Awards of restricted stock during the six months ended June 30, 2018 were not material, and we did not issue awards of restricted stock during the six months ended June 30, 2017.

We issued approximately 92,000 and 318,000 shares of common stock following the exercise or vesting of underlying stock options or restricted stock units in the six months ended June 30, 2018 and 2017, respectively.

Net Income per Share

6 Months Ended

Jun. 30, 2018

Earnings Per Share [Abstract]

Net Income per Share

10. Net Income per Share

The computation of basic and diluted net income per share was as follows:


	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017
	(in thousands, except per share data)				(in thousands, except per share data)
Basic:
Net income available for common stockholders	$	8,751	$	4,632	$	12,604	$	7,851

Weighted average shares outstanding		19,320		18,816		19,301		18,724

Basic earnings per share	$	0.45	$	0.25	$	0.65	$	0.42

Diluted:
Net income available for common stockholders	$	8,751	$	4,632	$	12,604	$	7,851

Weighted-average shares outstanding		19,320		18,816		19,301		18,724
Common stock equivalents, if dilutive		940		1,159		942		1,131

Shares used in computing diluted earnings per common share		20,260		19,975		20,243		19,855

Diluted earnings per share	$	0.43	$	0.23	$	0.62	$	0.40

Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive		214		1		214		1

Stockholders' Equity

6 Months Ended

Jun. 30, 2018

Federal Home Loan Banks [Abstract]

Stockholders' Equity

11. Stockholders’ Equity

Share Repurchase Program

On July 25, 2017, our Board of Directors approved a stock repurchase program under which the Company was authorized to repurchase up to $7.5 million of its common stock through transactions on the open market, in privately negotiated purchases or otherwise. This program expired on July 25, 2018. We did not make any share repurchases under this program.

Dividends

In February 2011, our Board of Directors approved a policy for the payment of quarterly cash dividends on our common stock. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by our Board of Directors on a quarterly basis. The dividend activity for the periods presented is as follows:


Record Date	Payment Date		Per Share Amount		Dividend Payment
					(in thousands)
Fiscal Year 2018
March 22, 2018		April 5, 2018	$	0.070	$	1,351
May 22, 2018		June 7, 2018	$	0.070	$	1,353
Fiscal Year 2017
March 22, 2017		April 6, 2017	$	0.055	$	1,029
May 24, 2017		June 8, 2017	$	0.055	$	1,036
August 23, 2017		September 7, 2017	$	0.055	$	1,055
November 22, 2017		December 7, 2017	$	0.055	$	1,060

On July 23, 2018 our Board of Directors approved a quarterly cash dividend on our common stock of $0.07 per share payable on September 6, 2018 to stockholders of record at the close of business on August 22, 2018, which will total approximately $1.4 million.

Supplemental Cash Flow Information

6 Months Ended

Jun. 30, 2018

Supplemental Cash Flow Elements [Abstract]

Supplemental Cash Flow Information

12. Supplemental Cash Flow Information


	Six months ended June 30.
	2018		2017
	(in thousands)
Cash paid for income taxes, net	$	3,140	$	2,825

Fair Value Measurements

6 Months Ended

Jun. 30, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements

13. Fair Value Measurements

The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

•

Level 1 — Quoted prices in active markets for identical assets or liabilities.

•

Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

•

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

Level 1 assets being measured at fair value on a recurring basis as of June 30, 2018 included our short-term investment mutual fund account.

We had no Level 2 assets being measured at fair value on a recurring basis as of June 30, 2018.

As discussed in Note 4, several of our acquisition-related assets and liabilities have been measured using Level 3 techniques. During 2016, we recorded contingent liabilities associated with our acquisitions of the RestoreFlow allograft and ProCol biologic graft businesses. In the case of the Restore Flow allograft acquisition, the agreement included the potential for us to pay up to $5.1 million of additional consideration, with $1.1 million contingent on the continued employment by LeMaitre of certain retained employees, and another $4.0 million contingent on the achievement of specified levels of revenues in the first 12 and 24 months following the acquisition date. This additional consideration was initially valued in total at $1.0 million and is being re-measured each reporting period until the payment requirement ends, with any adjustments reported in income from operations. The amount attributable to the first 12 months of revenue following the acquisition date was not paid as the associated revenue metric was not achieved. The amount that was contingent on the continued employment by LeMaitre of certain retained employees was paid in May 2018 as the contingency was met.

In the case of ProCol, additional consideration is payable to the former shareholders for a three-year period following the closing, calculated at 10% of ProCol revenues. This additional consideration was initially valued at $0.3 million and is being re-measured each reporting period until the payment requirement ends, with any adjustments reported in income from operations. These arrangements are described more fully in Note 4.

The following table provides a rollforward of the fair value of these liabilities, as determined by Level 3 unobservable inputs including management’s forecast of future revenues for these acquired businesses, as well as, in the case of the Restore Flow allograft acquisition, management’s estimate of the likelihood of continued employment of certain retained employees.


	Six months ended June 30,
	2018			2017
	(in thousands)
Beginning balance	$	1,300		$	1,320
Additions		—			—
Payments		(1,142	)		(51	)
Change in fair value included in earnings		42			35

Ending balance	$	200		$	1,304

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Accumulated Other Comprehensive Loss

6 Months Ended

Jun. 30, 2018

Equity [Abstract]

Accumulated Other Comprehensive Loss

14. Accumulated Other Comprehensive Loss


	Six months ended June 30,
	2018			2017
	(in thousands)
Beginning balance	$	(2,289	)	$	(4,583	)
Other comprehensive income (loss) before reclassifications		(918	)		1,639
Amounts reclassified from accumulated other comprehensive loss		—			—

Ending Balance	$	(3,207	)	$	(2,944	)

Changes to our accumulated other comprehensive loss consisted primarily of foreign currency translation for the six months ended June 30, 2018 and 2017.

Organization and Basis for Presentation (Policies)

6 Months Ended

Jun. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Basis of Presentation

Consolidation

Consolidation

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Segment Reporting

Fair Value Measurement

The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

•

Level 1 — Quoted prices in active markets for identical assets or liabilities.

•

Organization and Basis for Presentation (Tables)

6 Months Ended

Jun. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Disaggregation of Revenue by Major Geographic Area


	Six months ended June 30,
	2018		2017
Americas	$	31,942	$	31,069
Europe, Middle East and Africa		17,829		15,734
Asia/Pacific Rim		3,243		3,089

Total	$	53,014	$	49,892

Income Tax Expense (Tables)

6 Months Ended

Jun. 30, 2018

Income Tax Disclosure [Abstract]

Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits

A reconciliation of beginning and ending amount of our unrecognized tax benefits is as follows:


	Six months ended June 30, 2018
	(in thousands)
Unrecognized tax benefits as of December 31, 2017		525
Additions for tax positions of current year		48
Additions for tax positions of prior years		5
Reductions for settlements with taxing authorities		—
Reductions for lapses of the applicable statutes of limitations		—

Unrecognized tax benefits as of June 30, 2018		578

Summary of Tax Years Subject to Examination in Taxing Jurisdictions

As of June 30, 2018, a summary of the tax years that remain subject to examination in our taxing jurisdictions is as follows:


United States			2014 and forward
Foreign			2011 and forward

Inventories and Other Deferred Costs (Tables)

6 Months Ended

Jun. 30, 2018

Text Block [Abstract]

Summary of Inventories and Other Deferred Costs

Inventories and other deferred costs consist of the following:


	June 30, 2018		December 31, 2017
	(in thousands)
Raw materials	$	3,549	$	3,200
Work-in-process		4,253		3,745
Finished products		12,668		12,278
Other deferred costs		1,199		1,823

Total inventory and other deferred costs	$	21,669	$	21,046

Acquisitions and Divestitures (Tables)

6 Months Ended

Jun. 30, 2018

Summary of Allocation of Consideration Received

The following table summarizes the allocation of consideration received:


	Allocated Fair Value
	(in thousands)
Inventory	$	308
Deferred revenue—transition services agreement		1,081
Goodwill		135
Gain on divestiture		5,876

Consideration received	$	7,400

Restore Flow Allografts [Member]

Summary of Purchase Price Allocation

The following table summarizes the final purchase price allocation:


	Allocated Fair Value
	(in thousands)
Accounts receivable	$	394
Deferred cryopreservation costs		2,583
Equipment and supplies		125
Accounts payable		(286	)
Intangible assets		4,544
Goodwill		5,599

Purchase price	$	12,959

Acquired Intangible Assets and Related Estimated Useful Lives

The following table reflects the allocation of purchase consideration to the acquired intangible assets and related estimated useful lives:


	Allocated Fair Value		Weighted Average Useful Life
	(in thousands)
Non-compete agreements	$	180		5.0 years
Tradename		271		9.0 years
Procurement contracts		617		9.0 years
Technology		2,793		10.5 years
Customer relationships		683		12.5 years

Total intangible assets	$	4,544

ProCol Biologic Graft [Member]

Summary of Purchase Price Allocation

The following table summarizes the purchase price allocation as of the acquisition date:


	Allocated Fair Value
	(in thousands)
Inventory	$	2,080
Manufacturing equipment and supplies		25
Intangible assets		620
Goodwill		318

Purchase price	$	3,043

Acquired Intangible Assets and Related Estimated Useful Lives

The following table reflects the allocation of purchase consideration to the acquired intangible assets and related estimated useful lives:


	Allocated Fair Value		Weighted Average Useful Life
	(in thousands)
Non-compete agreement	$	84		5.0 years
Tradename		109		9.5 years
Intellectual property		277		9.0 years
Customer relationships		150		9.0 years

Total intangible assets	$	620

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Goodwill and Other Intangibles (Tables)

6 Months Ended

Jun. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

Goodwill consists of the following as of June 30, 2018:


	(in thousands)
Balance at December 31, 2017	$	23,844
Divestiture adjustment		(135	)
Effects of currency exchange		(107	)

Balance at June 30, 2018	$	23,602

Components of Identifiable Intangible Assets

Other intangible assets consist of the following:


	June 30, 2018						December 31, 2017
	Gross Carrying Value		Accumulated Amortization		Net Carrying Value		Gross Carrying Value		Accumulated Amortization		Net Carrying Value
	(in thousands)
Product technology	$	10,197	$	5,295	$	4,902	$	10,267	$	4,908	$	5,359
Trademarks and licenses		1,943		1,511		432		1,948		1,468		480
Customer relationships		5,317		3,535		1,782		5,383		3,299		2,084
Other intangible assets		1,567		1,325		242		1,575		1,264		311

Total identifiable intangible assets	$	19,024	$	11,666	$	7,358	$	19,173	$	10,939	$	8,234

Amortization Expense Included in General and Administrative Expense

Amortization expense is included in general and administrative expense and was as follows for the periods indicated.


	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017
	(in thousands)				(in thousands)
Amortization expense	$	414	$	456	$	832	$	910

We estimate that amortization expense for the remainder of 2018 and for each of the five succeeding fiscal years will be as follows:


	Year ended December 31,
	2018		2019		2020		2021		2022		2023
	(in thousands)
Amortization expense	$	750	$	1,377	$	1,122	$	923	$	713	$	680

Accrued Expenses and Other Long-term Liabilities (Tables)

6 Months Ended

Jun. 30, 2018

Payables and Accruals [Abstract]

Accrued Expenses

Accrued expenses consist of the following:


	June 30, 2018		December 31, 2017
	(in thousands)
Compensation and related taxes	$	5,618	$	6,494
Income and other taxes		1,565		703
Professional fees		61		35
Deferred revenue		951		—
Other		3,091		2,538

Total	$	11,286	$	9,770

Summary of Changes in Deferred Revenue

The following table summarizes the changes in the deferred revenue balance during the three months ended June 30, 2018:


	June 30, 2018
	(in thousands)
Beginning contract liability balance	$	—
Deferred revenue recorded		1,081
Revenue recognized upon satisfaction of performance obligations in the period		(130	)

Ending balance	$	951

Schedule of Other Long-term Liabilities

Other long-term liabilities consist of the following:


	June 30, 2018		December 31, 2017
	(in thousands)
Aquisition-related liabilities	$	—	$	127
Deferred rent		547		561
Income taxes		327		321
Other		192		179

Total	$	1,066	$	1,188

Segment and Enterprise-Wide Disclosures (Tables)

6 Months Ended

Jun. 30, 2018

Segment Reporting [Abstract]

Net Sales to Unaffiliated Customers by Geography

Net sales to unaffiliated customers by country were as follows:


	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017
	(in thousands)				(in thousands)
United States	$	14,864	$	14,932	$	29,684	$	28,979
Germany		3,257		2,854		6,364		5,739
Other countries		8,899		7,967		16,966		15,174

Net Sales	$	27,020	$	25,753	$	53,014	$	49,892

Share-based Compensation (Tables)

6 Months Ended

Jun. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Compensation Expense

The components of share-based compensation expense were as follows:


	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017
	(in thousands)				(in thousands)
Stock option awards	$	391	$	310	$	780	$	624
Restricted stock units		245		161		477		335

Total share-based compensation	$	636	$	471	$	1,257	$	959

Schedule of Stock-based Compensation

Stock-based compensation is included in our statements of operations as follows:


	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017
	(in thousands)				(in thousands)
Cost of sales	$	83	$	41	$	148	$	94
Sales and marketing		136		114		273		230
General and administrative		351		271		702		546
Research and development		66		45		134		89

Total stock-based compensation	$	636	$	471	$	1,257	$	959

Net Income per Share (Tables)

6 Months Ended

Jun. 30, 2018

Earnings Per Share [Abstract]

Computation of Basic and Diluted Net Income per Share

The computation of basic and diluted net income per share was as follows:


	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017
	(in thousands, except per share data)				(in thousands, except per share data)
Basic:
Net income available for common stockholders	$	8,751	$	4,632	$	12,604	$	7,851

Weighted average shares outstanding		19,320		18,816		19,301		18,724

Basic earnings per share	$	0.45	$	0.25	$	0.65	$	0.42

Diluted:
Net income available for common stockholders	$	8,751	$	4,632	$	12,604	$	7,851

Weighted-average shares outstanding		19,320		18,816		19,301		18,724
Common stock equivalents, if dilutive		940		1,159		942		1,131

Shares used in computing diluted earnings per common share		20,260		19,975		20,243		19,855

Diluted earnings per share	$	0.43	$	0.23	$	0.62	$	0.40

Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive		214		1		214		1

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2018

Federal Home Loan Banks [Abstract]

Dividend Activity

The dividend activity for the periods presented is as follows:


Record Date	Payment Date		Per Share Amount		Dividend Payment
					(in thousands)
Fiscal Year 2018
March 22, 2018		April 5, 2018	$	0.070	$	1,351
May 22, 2018		June 7, 2018	$	0.070	$	1,353
Fiscal Year 2017
March 22, 2017		April 6, 2017	$	0.055	$	1,029
May 24, 2017		June 8, 2017	$	0.055	$	1,036
August 23, 2017		September 7, 2017	$	0.055	$	1,055
November 22, 2017		December 7, 2017	$	0.055	$	1,060

Supplemental Cash Flow Information (Tables)

6 Months Ended

Jun. 30, 2018

Supplemental Cash Flow Elements [Abstract]

Supplemental Cash Flow Information


	Six months ended June 30.
	2018		2017
	(in thousands)
Cash paid for income taxes, net	$	3,140	$	2,825

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2018

Fair Value Disclosures [Abstract]

Rollforward of the Fair Value as Determined by Level 3


	Six months ended June 30,
	2018			2017
	(in thousands)
Beginning balance	$	1,300		$	1,320
Additions		—			—
Payments		(1,142	)		(51	)
Change in fair value included in earnings		42			35

Ending balance	$	200		$	1,304

Accumulated Other Comprehensive Loss (Tables)

6 Months Ended

Jun. 30, 2018

Equity [Abstract]

Summary of Accumulated Other Comprehensive Loss


	Six months ended June 30,
	2018			2017
	(in thousands)
Beginning balance	$	(2,289	)	$	(4,583	)
Other comprehensive income (loss) before reclassifications		(918	)		1,639
Amounts reclassified from accumulated other comprehensive loss		—			—

Ending Balance	$	(3,207	)	$	(2,944	)

Organization and Basis for Presentation - Summary of Disaggregation of Revenue by Major Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 27,020	$ 25,753	$ 53,014	$ 49,892
Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue from contract with customer			31,942	31,069
EMEA [Member]
Disaggregation of Revenue [Line Items]
Revenue from contract with customer			17,829	15,734
Asia Pacific [Member]
Disaggregation of Revenue [Line Items]
Revenue from contract with customer			$ 3,243	$ 3,089

Organization and Basis for Presentation - Additional Information (Detail)	Jun. 30, 2018
Minimum [Member]
Disaggregation of Revenue [Line Items]
Period of payments received from customers	30 days
Maximum [Member]
Disaggregation of Revenue [Line Items]
Period of payments received from customers	60 days

Income Tax Expense - Additional Information (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Corporate income tax rate	21.00%	35.00%
2017 Tax Act, one-time transition tax expense	$ 600
2017 Tax Act, remeasurement of deferred taxes, tax benefit	1,000
Unrecognized tax benefits exclusive of interest and penalties, gross	$ 578	$ 525
Statute of limitations expiration period	2025

Income Tax Expense - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2018 USD ($)
Income Tax Disclosure [Abstract]
Unrecognized tax benefits as of December 31, 2017	$ 525
Additions for tax positions of current year	48
Additions for tax positions of prior years	5
Reductions for settlements with taxing authorities	0
Reductions for lapses of the applicable statutes of limitations	0
Unrecognized tax benefits as of June 30, 2018	$ 578

Income Tax Expense - Summary of Tax Years Subject to Examination in Taxing Jurisdictions (Detail)	6 Months Ended
	Jun. 30, 2018
United States [Member]
Income Tax Examination [Line Items]
Income tax year under examination	2014 and forward
Foreign [Member]
Income Tax Examination [Line Items]
Income tax year under examination	2011 and forward

Inventories and Other Deferred Costs - Summary of Inventories and Other Deferred Costs (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 3,549	$ 3,200
Work-in-process	4,253	3,745
Finished products	12,668	12,278
Other deferred costs	1,199	1,823
Total inventory and other deferred costs	$ 21,669	$ 21,046

Inventories and Other Deferred Costs - Additional Information (Detail) - USD ($) $ in Millions	Jun. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventory on consignment	$ 1.4	$ 1.4

Acquisition and Divestitures - Restore Flow Allografts - Additional Information (Detail) - USD ($)		3 Months Ended		6 Months Ended
	Nov. 10, 2016	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Business Acquisition [Line Items]
Net revenue		$ 27,020,000	$ 25,753,000	$ 53,014,000	$ 49,892,000
Weighted average useful life				8 years
Restore Flow Allografts [Member]
Business Acquisition [Line Items]
Initial purchase price	$ 12,000,000
Acquisition-related contingent consideration	$ 900,000	$ 2,000,000		$ 2,000,000
Additional payment description				One payment of $2 million was due not later than 15 days following the expiration of the 18 month period following the closing date, subject to reductions as specified in the agreement for each calendar month that certain retained employees were not employed by us due to resignation without good reason, or termination for cause, both as defined in the agreement. The portion of this payment that was to be paid to retained employees and that was contingent on their continued employment, estimated at $0.9 million, was being accounted for as post-combination compensation expense rather than purchase consideration. The remaining $1.1 million that was payable to non-employee investors but that was also contingent on the continued employment of the retained employees had been accounted for as contingent purchase consideration, at an acquisition-date fair value of $0.9 million. During the three months ended June 30, 2018 we paid this $2 million liability as the contingency was met. There are also two potential earn-out payments under the agreement. The first earn-out was to be calculated at 50% of the amount by which net revenue in the first 12 months following the closing exceeded $6 million, with such payout not to exceed $2 million. This milestone was not met and accordingly no amount was paid out. The second earn-out is calculated at 50% of the amount by which net revenue in the second 12 months following the closing exceeds $9 million, with such payout not to exceed $2 million.
Estimated weighted average cost of capital	14.10%
Maximum goodwill deductible for tax purposes				15 years
Weighted average useful life				10 years 3 months 18 days
Restore Flow Allografts [Member] \| Non-employee Investors [Member]
Business Acquisition [Line Items]
Acquisition-related contingent consideration	$ 1,100,000
Acquisition-date fair value	900,000
Restore Flow Allografts [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Acquisition-related contingent consideration	6,000,000
Restore Flow Allografts [Member] \| Contingency One [Member]
Business Acquisition [Line Items]
Acquisition-related contingent consideration	2,000,000
Restore Flow Allografts [Member] \| Earn - Outs Payment One [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Acquisition-related contingent consideration	2,000,000
Restore Flow Allografts [Member] \| Earn - Outs Payment One [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Net revenue	6,000,000
Restore Flow Allografts [Member] \| Earn - Outs Payment Two [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Acquisition-related contingent consideration	2,000,000
Restore Flow Allografts [Member] \| Earn - Outs Payment Two [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Net revenue	9,000,000
Restore Flow Allografts [Member] \| Combined Earn-out Payment [Member]
Business Acquisition [Line Items]
Acquisition-date fair value	$ 100,000

Acquisition and Divestitures - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017	Mar. 18, 2016
Business Acquisition [Line Items]
Goodwill	$ 23,602	$ 23,844
Restore Flow Allografts [Member]
Business Acquisition [Line Items]
Accounts receivable	394
Deferred cryopreservation costs	2,583
Manufacturing equipment and supplies	125
Accounts payable	(286)
Intangible assets	4,544
Goodwill	5,599
Purchase price	$ 12,959
ProCol Biologic Graft [Member]
Business Acquisition [Line Items]
Inventory			$ 2,080
Manufacturing equipment and supplies			25
Intangible assets			620
Goodwill			318
Purchase price			$ 3,043

Acquisition and Divestitures - Acquired Intangible Assets and Related Estimated Useful Lives (Detail) - USD ($) $ in Thousands		6 Months Ended
	Mar. 18, 2016	Jun. 30, 2018
Business Acquisition [Line Items]
Weighted average useful life		8 years
Restore Flow Allografts [Member]
Business Acquisition [Line Items]
Allocated fair value		$ 4,544
Weighted average useful life		10 years 3 months 18 days
Restore Flow Allografts [Member] \| Non-Compete Agreement [Member]
Business Acquisition [Line Items]
Allocated fair value		$ 180
Weighted average useful life		5 years
Restore Flow Allografts [Member] \| Trade Name [Member]
Business Acquisition [Line Items]
Allocated fair value		$ 271
Weighted average useful life		9 years
Restore Flow Allografts [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Allocated fair value		$ 683
Weighted average useful life		12 years 6 months
Restore Flow Allografts [Member] \| Procurement Contracts [Member]
Business Acquisition [Line Items]
Allocated fair value		$ 617
Weighted average useful life		9 years
Restore Flow Allografts [Member] \| Technology [Member]
Business Acquisition [Line Items]
Allocated fair value		$ 2,793
Weighted average useful life		10 years 6 months
ProCol Biologic Graft [Member]
Business Acquisition [Line Items]
Allocated fair value	$ 620
Weighted average useful life		8 years 7 months 6 days
ProCol Biologic Graft [Member] \| Non-Compete Agreement [Member]
Business Acquisition [Line Items]
Allocated fair value	$ 84
Weighted average useful life	5 years
ProCol Biologic Graft [Member] \| Trade Name [Member]
Business Acquisition [Line Items]
Allocated fair value	$ 109
Weighted average useful life	9 years 6 months
ProCol Biologic Graft [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Allocated fair value	$ 150
Weighted average useful life	9 years
ProCol Biologic Graft [Member] \| Intellectual Property [Member]
Business Acquisition [Line Items]
Allocated fair value	$ 277
Weighted average useful life	9 years

Acquisition and Divestitures - ProCol Biologic Graft - Additional Information (Detail) - USD ($) $ in Millions		6 Months Ended
	Mar. 18, 2016	Jun. 30, 2018
Business Acquisition [Line Items]
Weighted average useful life		8 years
ProCol Biologic Graft [Member]
Business Acquisition [Line Items]
Purchase price for acquisition of assets and rights	$ 2.7
Business combination, finished goods inventory and other related assets acquired	2.0
Business combination, other assets acquired	$ 0.7
Business combination consideration calculated, percentage of revenues	10.00%
Additional consideration initial value	$ 0.3
Payment made for assets purchased, percentage	50.00%
Maximum goodwill deductible for tax purposes	15 years
Weighted average useful life		8 years 7 months 6 days

Acquisition and Divestitures - Subsequent Event - Reddick Divestiture - Additional Information (Detail) - Specialty Surgical Instrumentation, Inc [Member] - Reddick Cholangiogram Catheter and Reddick Saye-Screw [Member] - USD ($)		3 Months Ended
	Apr. 05, 2018	Jun. 30, 2018
Business Acquisition [Line Items]
Proceeds from sale of assets	$ 7,400,000
Gain on sale of assets		$ 5,900,000
Purchase agreement period	2 years
Balloon Supply Agreement [Member]
Business Acquisition [Line Items]
Purchase agreement period	6 years

Acquisitions and Divestitures - Summary of Allocation of Consideration Received (Detail) - Specialty Surgical Instrumentation, Inc [Member] - Reddick Cholangiogram Catheter and Reddick Saye-Screw [Member] $ in Thousands	Apr. 05, 2018 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Inventory	$ 308
Deferred revenue-transition services agreement	1,081
Goodwill	135
Gain on divestiture	5,876
Consideration received	$ 7,400

Goodwill and Other Intangibles - Schedule of Goodwill (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2018 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Balance at December 31, 2017	$ 23,844
Divestiture adjustment	(135)
Effects of currency exchange	(107)
Balance at June 30, 2018	$ 23,602

Goodwill and Other Intangibles - Components of Identifiable Intangible Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 19,024	$ 19,173
Accumulated Amortization	11,666	10,939
Net Carrying Value of Intangible Assets	7,358	8,234
Product Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	10,197	10,267
Accumulated Amortization	5,295	4,908
Net Carrying Value of Intangible Assets	4,902	5,359
Trademarks and Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	1,943	1,948
Accumulated Amortization	1,511	1,468
Net Carrying Value of Intangible Assets	432	480
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	5,317	5,383
Accumulated Amortization	3,535	3,299
Net Carrying Value of Intangible Assets	1,782	2,084
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	1,567	1,575
Accumulated Amortization	1,325	1,264
Net Carrying Value of Intangible Assets	$ 242	$ 311

Goodwill and Other Intangibles - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2018
Finite-Lived Intangible Assets [Line Items]
Weighted-average amortization period for intangibles	8 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful lives	13 years
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets useful lives	3 years

Goodwill and Other Intangibles - Amortization Expense Included in General and Administrative Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 414	$ 456	$ 832	$ 910	$ 680	$ 713	$ 923	$ 1,122	$ 1,377	$ 750

Accrued Expenses and Other Long-term Liabilities - Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Compensation and related taxes	$ 5,618	$ 6,494
Income and other taxes	1,565	703
Professional fees	61	35
Deferred revenue	951
Other	3,091	2,538
Total	$ 11,286	$ 9,770

Accrued Expenses and Other Long-term Liabilities - Summary of Changes in Deferred Revenue (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2018 USD ($)
Deferred Revenue Disclosure [Abstract]
Beginning balance	$ 0
Deferred revenue recorded	1,081
Revenue recognized upon satisfaction of performance obligations in the period	(130)
Ending balance	$ 951

Accrued Expenses and Other Long-term Liabilities - Schedule of Other Long-term Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Other Liabilities, Noncurrent [Abstract]
Aquisition-related liabilities		$ 127
Deferred rent	$ 547	561
Income taxes	327	321
Other	192	179
Total	$ 1,066	$ 1,188

Segment and Enterprise-wide Disclosures - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2018 Segment
Segment Reporting [Abstract]
Number of operating segments	1

Segment and Enterprise-wide Disclosures - Net Sales to Unaffiliated Customers by Geography (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Segment Reporting Information [Line Items]
Net sales	$ 27,020	$ 25,753	$ 53,014	$ 49,892
United States [Member]
Segment Reporting Information [Line Items]
Net sales	14,864	14,932	29,684	28,979
Germany [Member]
Segment Reporting Information [Line Items]
Net sales	3,257	2,854	6,364	5,739
Other Countries [Member]
Segment Reporting Information [Line Items]
Net sales	$ 8,899	$ 7,967	$ 16,966	$ 15,174

Share-based Compensation - Share-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Schedule of Trading Securities and Other Trading Assets [Line Items]
Total share-based compensation	$ 636	$ 471	$ 1,257	$ 959
Stock Option Awards [Member]
Schedule of Trading Securities and Other Trading Assets [Line Items]
Total share-based compensation	391	310	780	624
Restricted Stock Units [Member]
Schedule of Trading Securities and Other Trading Assets [Line Items]
Total share-based compensation	$ 245	$ 161	$ 477	$ 335

Share-based Compensation - Schedule of Stock-based Compensation (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 636	$ 471	$ 1,257	$ 959
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	83	41	148	94
Sales and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	136	114	273	230
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	351	271	702	546
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 66	$ 45	$ 134	$ 89

Share-based Compensation - Additional Information (Detail) - shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted	0
Issue of common stock	92,000	318,000
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units issued	0	0

Net Income per Share - Computation of Basic and Diluted Net Income per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Basic:
Net income available for common stockholders	$ 8,751	$ 4,632	$ 12,604	$ 7,851
Weighted average shares outstanding	19,320	18,816	19,301	18,724
Basic earnings per share	$ 0.45	$ 0.25	$ 0.65	$ 0.42
Diluted:
Net income available for common stockholders	$ 8,751	$ 4,632	$ 12,604	$ 7,851
Weighted-average shares outstanding	19,320	18,816	19,301	18,724
Common stock equivalents, if dilutive	940	1,159	942	1,131
Shares used in computing diluted earnings per common share	20,260	19,975	20,243	19,855
Diluted earnings per share	$ 0.43	$ 0.23	$ 0.62	$ 0.40
Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive	214	1	214	1

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Stockholders' Equity - Additional Information (Detail) - USD ($)		3 Months Ended		6 Months Ended
	Jul. 23, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Jul. 25, 2017
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Cash dividend on common stock per share		$ 0.070	$ 0.055	$ 0.140	$ 0.110
Installment 2 FY 2018 [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Dividend payment date				Sep. 06, 2018
Dividend record date				Aug. 22, 2018
Subsequent Event [Member] \| Installment 2 FY 2018 [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Cash dividend on common stock per share	$ 0.07
Dividend Payment	$ 1,400,000
Stock Repurchase Program [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Stock repurchase program expiration date				Jul. 25, 2018
Stock repurchase program, Description				This program expired on July 25, 2018.
Share repurchases				0
Stock Repurchase Program [Member] \| Maximum [Member] \| Common Stock [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Repurchase of common stock						$ 7,500,000

Stockholders' Equity - Dividend Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Feb. 28, 2011	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Jun. 07, 2018	Apr. 05, 2018	Dec. 07, 2017	Sep. 07, 2017	Jun. 08, 2017	Apr. 06, 2017
Dividends Payable [Line Items]
Per Share Amount		$ 0.070	$ 0.055	$ 0.140	$ 0.110
Installment FY 2018 [Member]
Dividends Payable [Line Items]
Record Date				Mar. 22, 2018
Payment Date				Apr. 05, 2018
Per Share Amount	$ 0.070
Dividend Payment							$ 1,351
Installment 1 FY 2018 [Member]
Dividends Payable [Line Items]
Record Date				May 22, 2018
Payment Date				Jun. 07, 2018
Per Share Amount	0.070
Dividend Payment						$ 1,353
Installment 1 FY 2017 [Member]
Dividends Payable [Line Items]
Record Date				Mar. 22, 2017
Payment Date				Apr. 06, 2017
Per Share Amount	0.055
Dividend Payment											$ 1,029
Installment 2 FY 2017 [Member]
Dividends Payable [Line Items]
Record Date				May 24, 2017
Payment Date				Jun. 08, 2017
Per Share Amount	0.055
Dividend Payment										$ 1,036
Installment 3 FY 2017 [Member]
Dividends Payable [Line Items]
Record Date				Aug. 23, 2017
Payment Date				Sep. 07, 2017
Per Share Amount	0.055
Dividend Payment									$ 1,055
Installment 4 FY 2017 [Member]
Dividends Payable [Line Items]
Record Date				Nov. 22, 2017
Payment Date				Dec. 07, 2017
Per Share Amount	$ 0.055
Dividend Payment								$ 1,060

Supplemental Cash Flow Information - Supplemental Cash Flow Information (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Supplemental Cash Flow Elements [Abstract]
Cash paid for income taxes, net	$ 3,140	$ 2,825

Fair Value Measurements - Additional Information (Detail) - USD ($)	Mar. 18, 2016	Jun. 30, 2018	Nov. 10, 2016
Restore Flow Allografts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration		$ 2,000,000	$ 900,000
Restore Flow Allografts [Member] \| Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration			6,000,000
Restore Flow Allografts [Member] \| Non-employee Investors [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration			1,100,000
Acquisition-date fair value			900,000
ProCol Biologic Graft [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination consideration calculated, percentage of revenues	10.00%
Additional consideration initial value	$ 300,000
Level 2 [Member] \| Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value		$ 0
Fair Value, Inputs, Level 3 [Member] \| Restore Flow Allografts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition-date fair value			1,000,000
Fair Value, Inputs, Level 3 [Member] \| Restore Flow Allografts [Member] \| Earn Out Payment [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration			4,000,000
Fair Value, Inputs, Level 3 [Member] \| Restore Flow Allografts [Member] \| Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration			5,100,000
Fair Value, Inputs, Level 3 [Member] \| Restore Flow Allografts [Member] \| Non-employee Investors [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration			$ 1,100,000
Fair Value, Inputs, Level 3 [Member] \| ProCol Biologic Graft [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination consideration calculated, percentage of revenues	10.00%
Additional consideration initial value	$ 300,000

Fair Value Measurements - Rollforward of the Fair Value as Determined by Level 3 (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Beginning balance	$ 1,300	$ 1,320
Additions	0	0
Payments	(1,142)	(51)
Change in fair value included in earnings	42	35
Ending balance	$ 200	$ 1,304

Accumulated Other Comprehensive Loss - Summary of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	$ 109,770
Ending Balance	120,744
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(2,289)	$ (4,583)
Other comprehensive income (loss) before reclassifications	(918)	1,639
Amounts reclassified from accumulated other comprehensive loss	0	0
Ending Balance	$ (3,207)	$ (2,944)